Literature DB >> 12916557

Management of acute stroke.

Richard M Zweifler1.   

Abstract

Stroke ranks as the third leading cause of death and the most common cause of permanent disability in adults. Timely recognition and treatment is imperative to reduce stroke-related morbidity and mortality. Patients with acute ischemic stroke should be evaluated for administration of intravenous tissue plasminogen activator (t-PA); those who do not qualify for t-PA should receive aspirin therapy in the absence of a contraindication. In all stroke patients, intravenous hydration with normal saline should be administered, hypoxia should be corrected with supplemental oxygen, and hyperglycemia and fever should be treated aggressively. Blood pressure management should be individualized on the basis of stroke pathophysiology and specific treatment plan (e.g., planned thrombolysis) following published guidelines. Evaluation of stroke etiology should be undertaken, and the results should be used to guide secondary stroke prevention efforts.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12916557     DOI: 10.1097/01.SMJ.0000063467.75456.7A

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

Review 1.  Cytochrome P450 eicosanoids and cerebral vascular function.

Authors:  John D Imig; Alexis N Simpkins; Marija Renic; David R Harder
Journal:  Expert Rev Mol Med       Date:  2011-03-01       Impact factor: 5.600

Review 2.  Treating the acute stroke patient as an emergency: current practices and future opportunities.

Authors:  S Davis; K Lees; G Donnan
Journal:  Int J Clin Pract       Date:  2006-04       Impact factor: 2.503

3.  Retrospective audit of the acute management of stroke in two district general hospitals in the uk.

Authors:  O O Faluyi; J A Omodara; K H Tay; K Muhiddin
Journal:  Ann Ib Postgrad Med       Date:  2008-06

4.  Allopurinol as a preventive contrivance after acute ischemic stroke in patients with a high level of serum uric acid: a randomized, controlled trial.

Authors:  Ali Akbar Taheraghdam; Ehsan Sharifipour; Ali Pashapour; Shahryar Namdar; Abolfazl Hatami; Samaneh Houshmandzad; Elyar Sadeghihokmabadi; Mokhtar Tazik; Reza Rikhtegar; Ata Mahmoodpoor
Journal:  Med Princ Pract       Date:  2013-11-27       Impact factor: 1.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.